Neoleukin Therapeutics
$2.929876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.92
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.05 (-1.68%) Today
$0.00 (0.00%) As of 6:00 PM EST after-hours
Why Robinhood?
You can buy or sell NLTX and other stocks, options, ETFs, and crypto commission-free!
About NLTX
Neoleukin Therapeutics, Inc. Common Stock, also called Neoleukin Therapeutics, is a biopharmaceutical company, which engages in the design of de novo protein therapeutics to address significant unmet medical needs in oncology, inflammation, and autoimmunity. Read More Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
Employees
8
Headquarters
Seattle, Washington
Founded
2003
Market Cap
83.56M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
41.09K
High Today
$3.00
Low Today
$2.92
Open Price
$2.98
Volume
25.44K
52 Week High
$4.23
52 Week Low
$2.00